Kornimate/medical-research-clean huggingface dataset:
ability of a new design of iodine 125 seed to maintain intended position when implanted in the prostate

Conditions: Prostate Cancer

Summary: this study compares the ability of a new design of brachytherapy seed for prostate seed implants for treatment of prostate cancer to maintain their intended position in the prostate after being deposited. standard seeds, especially in apical locations, have a tendency to migrate distally in response to muscular forces. anchorseeds have a textured coating which is designed to prevent migration. 40 patients who are eligible and suitable for prostate brachytherapy will be randomly assigned to receive either standard seeds or anchorseeds.

standard post implant prostate brachytherapy quality assurance at the center for the southern interior is usually performed at one month after the procedure with ct and mr imaging. in order to test the ability of the new design of prostate brachytherapy seeds (anchorseeds) to hold their position in the prostate, 40 men who have been randomly assigned to receive either standard seeds or anchorseeds will have an additional ct scan immediately after the procedure to record seed position for comparison to positions one month later. the magnitude and frequency of seed displacement will be determined.

Eligibility criteria:
inclusion criteria: * localized prostate cancer * favorable or intermediate risk * suitable for permanent seed implant by functional and technical criteria exclusion criteria: * patient unwilling to have a second ct scan for study purposes * claustrophobic patient unable to have ct scan * patient unsuitable for brachytherapy because of prostate size or poor voiding function * patient medically unable to stop anticoagulants for procedure

Keywords: prostate cancer iodine 125 brachytherapy seed migration seed migration in the first month after brachytherapy
clinical features of severe patients with covid-19

Conditions: SARS-CoV2

Summary: as coronavirus disease 2019 (covid-19) spreads across the world, the intensive care unit (icu) community must prepare for the challenges associated with this pandemic. providing an efficient care to the patients of the most severely affected category - intensive care unit (icu) patients - has become one of the serious problems appearing in the covid-19 pandemics. a typical patient's clinical portrait in icu of covid centers is very similar in different countries, however, the key to improve the treatment results for critically ill patients has not yet been found. data on predictors of severe course in covid-19 is limited. knowledge of predictors of severe course of disease can lead to different selection of therapeutic strategy, determine the group of risk of patients for severe course of disease, and improve outcomes.

the clinical disease (covid-19) results in critical illness in about 5% of patients. the aim of the study is to identify predictors of the severe pneumonia caused by the sars-cov-2 virus, and to describe the clinical features of patients admitted to an icu of the covid-center of the federal research clinical center of federal medical \& biological agency on the first day and in dynamics till discharge from the icu or death. the demographic and clinical data will be collected. laboratory data (hemoglobin, lymphocytes, neutrophil to lymphocyte ratio, d-dimer level, il-6, procalcitonin, glucose level, high-sensitive troponin т, vitamin d level, signs of the presence of a secondary bacterial infection, immunogram and instrumental data (ct-scan, electrocardiography, echocardiography, arterial and venous ultrasound investigation) will be analysed. this study is singlecentral observational trial.

Eligibility criteria:
inclusion criteria: * all patients with covid-19 admitted to the icu with invasive and noninvasive ventilation exclusion criteria: * less than 24 hours in icu by any reason, * chronic decompensated diseases with extrapulmonary organ dysfunction (tumour progression, liver cirrhosis, congestive heart failure), * atonic coma.

Keywords: sars pneumonia covid-19 severe disease risk factors
switch to atazanavir and brachial artery reactivity (sabar) study

Conditions: HIV Infection; Hyperlipidemia

Summary: the purpose of this study is to evaluate the change in brachial artery reactivity in hiv-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen

hiv-infected subjects on a stable protease inhibitor (pi) containing antiretroviral regimen with plasma hiv rna \ 130 mg/dl or fasting triglycerides levels \>200 mg/dl, will be randomized (1:1) to continue their current antiretroviral regimen or to switch the pi to atazanavir (atv). brachial artery reactivity will be measured before (at entry) and 12 and 24 weeks after subjects are randomized. arm a: switch current pi to atazanavir 400 mg once daily plus current \> 2 nucleoside/nucleotide reverse transcriptase inhibitors (nrtis) for 24 weeks. subjects currently on ritonavir (rtv) (400 mg bid or greater) or rtv-boosted pi (\<400 mg/day) , or tenofovir (tdf) as backbone nrti therapy, will switch to atv 300 mg boosted with rtv 100mg once daily. arm b: continue current antiretroviral regimen (single or rtv-boosted pi plus \> 2 nrtis) for 24 weeks brachial artery reactivity in response to two vasoactive stimuli (increased forearm blood flow and nitroglycerin) will be assessed by measuring brachial artery diameter.

Eligibility criteria:
inclusion criteria: * hiv infection * hiv-1 rna \< 500 copies/ml * fasting ldl cholesterol \>130 mg/dl or fasting triglycerides \>200 mg/dl * cd4 count \>100 cells/mm * stable antiretroviral regimen for at least 12 weeks prior to study entry that includes a protease inhibitor (pi) with or without ritonavir boosting exclusion criteria: * history of heart disease, uncontrolled hypertension, peripheral vascular disease * current non-nucleoside reverse transcriptase inhibitor (nnrti) in the pi-containing regimen within 4 weeks * prior or current use of atazanavir * initiation of treatment with lipid-lowering drugs within 4 weeks prior to study entry

Keywords: atazanavir endothelial function treatment experienced
the effect of liraglutide compared to sitagliptin, both in combination with metformin on glycaemic control in subjects with type 2 diabetes mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe and north america. the aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes inadequately controlled with metformin alone. the trial has been extended by 52 weeks. the extension will consist of two 26-week periods: 1. week 27-52 after randomisation - all subjects will continue receiving sitagliptin or liraglutide at unchanged dose and dosing regimen. 2. week 53-78 after randomisation * subjects receiving sitagliptin at the end of week 52 after randomisation will discontinue sitagliptin and will be randomised 1:1 to liraglutide 1.2 mg/day or liraglutide 1.8 mg/day. liraglutide will be initiated at a dose of 0.6 mg/day, and increased to 1.2 mg/day or 1.8 mg/day in weekly intervals. * subjects receiving liraglutide 1.2 mg/day or 1.8 mg/day at the end of week 52 after randomisation will continue the treatment at unchanged dose and dosing regimen. trial completion is planned for june 2010.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * treatment with metformin alone for at least three months * hba1c (glycosylated haemoglobin a1c) 7.5-10.0% (both inclusive) * body mass index (bmi) less than or equal to 45.0 exclusion criteria: * previous treatment with insulin, glucagon like peptide-1 (glp-1) receptor agonists or dipeptidyl peptidase-4 (dpp-4) inhibitors * treatment with anti-diabetic drugs other than metformin within the last three months * any serious medical condition * females who are pregnant, have the intention of becoming pregnant or are breastfeeding
triple therapy with tegoprazan in h. pylori positive patients_pilot

Conditions: Helicobacter Pylori Infection

Summary: this study aims to compare safety and efficacy in an exploratory manner between a tegoprazan triple therapy and a rapae01 triple therapy in h. pylori positive patients.

a randomized, double-blind, active-controlled, multicenter, pilot study to investigate the safety and efficacy of a tegoprazan triple therapy and a rapae01 triple therapy in h. pylori positive patients.

Eligibility criteria:
inclusion criteria: * h. pylori positive at screening * subjects who have upper gastrointestinal disease exclusion criteria: * having received prior therapy for eradication of h. pylori * prior use of p-cab, proton pump inhibitors (ppis), h2 receptor blockers within 14 days * prior use of h. pylori eradication effective antibiotics, bismuth within 28 days
study of vitamin d and effect on heart disease and insulin resistance

Conditions: Human Immunodeficiency Virus (HIV); Vitamin D Deficiency; HIV Infections

Summary: the purpose of this study is to evaluate how vitamin d affects endothelial function, inflammation, lipids, insulin resistance, vitamin d levels, and parathyroid hormone (pth).

randomized placebo controlled trial of vitamin d supplementation in hiv infected subjects with vitamin d deficiency

Eligibility criteria:
inclusion criteria: * hiv infected * hiv-rna \< 400 copies/ml at study entry and for 12 wks. prior * 25-hydroxyvitamin d level \<20 * on a stable anti-retroviral (arv) regimen for at least 12 weeks prior to study entry exclusion criteria: * pregnancy or breast feeding * diabetes * creatinine clearance \<50 * any active infectious or inflammatory condition * aspartate aminotransferase (ast) or alanine aminotransferase (alt) \>2.5 within 6 months prior to study entry

Keywords: vitamin d human immunodeficiency virus (hiv) complementary therapies
support for perinatal adherence and depression

Conditions: Human Immunodeficiency Virus; Depression

Summary: the main aim was to conduct a pilot field test of a group-based depression and adherence counseling intervention with hiv-infected women in the perinatal period. participants were hiv-infected women living in kwazulu-natal, south africa.

the main aim of this study was to conduct a pilot field test of a group-based counseling intervention with hiv-infected women in the perinatal period as delivered by a lay counselor. the primary goal of the intervention was to reduce symptoms of perinatal depression and increase adherence to antiretroviral therapy among hiv-infected women during pregnancy and the postpartum period.

Eligibility criteria:
inclusion criteria: * currently pregnant * hiv-infected and diagnosed with hiv during the index pregnancy * meet criteria for a major depressive episode * currently on antiretroviral therapy * receiving antenatal care at pmmh gateway clinic * primary language english or isizulu * access to a phone and willing to give researchers permission to reach them via phone * resident of umlazi exclusion criteria: * unable or unwilling to provide informed consent * active untreated, major mental illness (untreated psychosis, bipolar disorder, dementia, or active suicidality) that would interfere with study participation * less than 18 years of age

Keywords: hiv medication adherence pmtct depression
bronchial hyper-responsiveness in reflux cough

Conditions: Cough

Summary: the study aim is to determine the effect of 8 weeks of anti-reflux treatment (full acid suppression) on bronchial hyper-responsiveness and whether there is a symptomatic improvement.


Eligibility criteria:
inclusion criteria: * positive methacholine challenge test pc20 less than 4mg/ml (can be previously documented in patients notes within last 4weeks) * written informed consent * patients with a history of chronic cough (at least 3 months duration), and associated symptoms of gastro-oesophageal reflux * male and female subjects of at least 18 yrs of age * subjects able to perform satisfactory fev1 manoeuvres * subjects able to understand the study and co-operate with the study procedures * subjects who consent to their general practitioner (gp) being informed of their study participation exclusion criteria: * has had a heart attack in the last three months * suffers from angina, hypertension or ischaemic heart disease * has epilepsy for which he/she is taking medication * fev1\< 60% predicted * fev1\<1.6l * female subjects who are pregnant, or lactating, or who are of child bearing potential but are not using contraceptive measures * suffering from any concomitant disease which may interfere with study procedures or evaluation. * a lower respiratory tract infection 4 weeks prior to entry on to study * participation in another study (use of investigational product) within 30 days preceding entry on to study. * alcohol or drug abuse * use of opiates to treat cough 1 week prior to enrollment * subjects who are taking angiotensin converting enzymes (ace) inhibitors. * subjects who have significant pathology on most recent chest x-ray. * inability to understand the procedures and the implications of a challenge test * patients already taking or have taken in last 4 weeks ppi and h2 receptor antagonist (full acid suppression treatment

Keywords: hyper-responsiveness, reflux cough
study of talabostat and pemetrexed vs. pemetrexed in stage iiib/iv non-small cell lung cancer (nsclc) after failure of platinum-based chemotherapy

Conditions: Carcinoma, Non-Small-Cell Lung; Lung Cancer; Neoplasms, Lung; Neoplasms, Pulmonary

Summary: this phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with stage iiib/iv nsclc who have failed a platinum-based chemotherapy regimen.


Eligibility criteria:
inclusion criteria: * men or women age ≥18 years * histologically or cytologically confirmed nsclc (recurrent, locally advanced or metastatic, inoperable nsclc \[stage iiib/iv\]. patients with stage iiib nsclc must have a cytologically documented pleural effusion.) * failed or relapsed after receiving a platinum-containing chemotherapy regimen as first-line therapy for advanced nsclc * measurable disease on computerized tomography (ct) scan * ecog performance status of 0 or 1 * expected survival ≥12 weeks * provide written informed consent exclusion criteria: * more than 2 prior chemotherapy regimens * progression of disease on prior pemetrexed treatment * brain metastases (exception: patients who had a resection and/or completed a course of cranial irradiation, have no worsening cns symptoms, and have discontinued all corticosteroids for that indication for at least 1 month) * serum creatinine ≥2.0mg/dl or creatinine clearance \<45ml/min * absolute neutrophil count \<1500/μl or platelets \<100,000/μl * any malignancy within 5 years immediately prior to the first dose of study medication (exception: basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix) * any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol * patients who are within 28 days of chemotherapy, radiation therapy, immunotherapy, or investigational medication for nsclc. patients must have recovered from all of the side effects of treatment. * pregnancy or lactation. women of childbearing potential and non-vasectomized men must agree to use a barrier method of contraception during treatment.
the efficacy of influenza vaccination in patients with coronary artery diseases

Conditions: Coronary Artery Diseases; Myocardial Infarction; Stable Angina

Summary: this study wishes to understand: 1. whether vaccination against influenza in coronary artery disease (myocardial infarction and stable angina) patients is as effective as it is in healthy subjects; 2. whether vaccination really decreases the episodes of influenza infection in those coronary artery disease patients who receive the vaccine than those who do not.

influenza infection may become complicated in patients with chronic conditions, including coronary artery disease (cad) \[1\]. influenza vaccination is now recommended as part of comprehensive secondary prevention in individuals with coronary and other atherosclerotic vascular disease (evidence level: class i, level b) \[2\]. although there is controversial evidence pro \[3,4\] and against \[5\] the efficacy of influenza vaccination in protecting cad population against cardiovascular events, the efficacy of vaccine in actual reduction in episodes of influenza infection and its fatal complications in cad patients has not been, to our knowledge, well studied before. furthermore, we found no report comparing serologic response to the influenza vaccine antigens between cad patients and healthy controls. this study aims to identify the efficacy of influenza vaccination in cad individuals in terms of both serologic response (as compared with healthy individuals) and clinical outcomes (as compared with cad patients not vaccinated).

Eligibility criteria:
inclusion criteria: * coronary artery disease (cad) group (cad-exp and cad-control): * patients with the diagnosis of acute, evolving or recent mi (after recovered the acute phase) as defined by: 1. typical rise and gradual fall (troponin) or more rapid rise and fall (ck-mb) of biochemical markers of myocardial necrosis with at least one of the following: * ischemic symptoms * development of pathologic qwaves on the ecg * ecg changes indicative of ischemia (st segment elevation or depression); or * coronary artery intervention (e.g., coronary angioplasty). 2. pathologic findings of an acute mi \[1\]: * patients with stable angina pectoris (sa) and documented coronary artery stenosis (angiography). * healthy control group: healthy controls, proportionally matched by gender and age with the patient group (separate control groups for mi and sa patients). exclusion criteria: * any acute disease * chronic liver or kidney diseases * conditions accompanied by immunosuppression (like organ transplantation, hiv) * diagnosed malignancy * incubation with influenza vaccine within the past 5 years * any psychological disease that interferes with regular follow-up * congestive heart failure (killip class iv) * unstable angina; and * contradictions of vaccine incubation (like egg allergy).

Keywords: coronary artery diseases myocardial infarction stable angina influenza vaccine
longevity of microwave thermolysis and botulinum toxin a for treatment of axillary hyperhidrosis

Conditions: Hyperhidrosis Primary Focal Axilla

Summary: this trial aims is to assess and compare treatment effect of microwave thermolysis and botulinum toxin a for axillary hyperhidrosis with focus on longevity. the investigators also aim to assess patient satisfaction and adverse reactions in relation to treatment.


Eligibility criteria:
inclusion criteria: 1. subject has provided written informed consent 2. subject is 18 years of age or older 3. a unilateral hdss score of 3 or 4 for each axilla 4. a gravimetric measurement of at least 50 mg/5 min for women and 100 mg/5 min for men in at least one axilla. the contralateral axilla should not be below 40 mg (women) and 80 mg (men). 5. women of childbearing potential must be confirmed not pregnant by a negative u-hcg prior to study treatment and must use a safe contraceptive method at baseline. exclusion criteria: 1. subjects with generalized hyperhidrosis 2. medical condition or medications that may alter perspiration (e.g. metabolic, immunological or infectious diseases, antidepressants, opioids, adrenergic/cholinergic drugs) 3. daily use of systemic or topical antibiotics and/or steroids in axillae at the time of inclusion 4. topical treatments for axillary hyperhidrosis (anti-perspirants are allowed except for visit days) 5. abnormal skin (e.g. rash, infection, dermatitis) in the axilla at the time of inclusion 6. breast tissue in the axillae 7. treatment with isotretinoin within the past 6 months 8. axillary laser or ipl treatment within the past 6 months 9. botulinum toxin-injections in the axillae within the past 12 months prior to baseline 10. known allergies to botulinum toxin, iodine, lidocaine or adrenaline 11. prior axillary surgery 12. limited motion in the shoulder joint or neurologic deficit in upper limb 13. history of diseases resulting in muscle weakness (als, lou gehrig's), dysphagia (myasthenia gravis or lambert eaton syndrome) or respiratory compromise 14. axillary lymph node enlargement or -removal or lymphedema in either upper limb 15. history of hidradenitis suppurativa or history of reoccurring infections/abscesses 16. history of breast cancer 17. electronic device implant 18. if female; lactating, pregnant or planning on becoming pregnant during the study 19. non-eligibility at the discretion of the investigator (e.g. non-compliance, unavailability or other reasons the subject is not believed to be able to comply with the clinical trial protocol)

Keywords: axillary hyperhidrosis microwave thermolysis botulinum toxin a
sentinel lymph node detection in prostate surgery by laparoscopy

Conditions: Prostatic Neoplasms

Summary: in this study the investigators want to determine if the detection of lymph node is applicable in prostatectomy by laparoscopy.


Eligibility criteria:
inclusion criteria: * age\> 18 years * diagnosis of invasive cancer of the prostate (t1 or t2 or t3) * psa ≥ 4, * gleason ≥ 6 * no treatment prior to surgery * indication of lymphadenectomy by coeliscopique * ecog or karnofsky index 2 * patient information and signed informed consent exclusion criteria: * neoadjuvant hormone therapy * interventions prior pelvic * patients who received anterior resection of part of prostate * patient or denied having an altered mental status * any contre indication to laparoscopy

Keywords: patients with infiltrant prostatic carcinoma
a patient-centered intervention using technology to reduce colorectal cancer disparities in primary care

Conditions: Colo-rectal Cancer

Summary: the purpose of this proposal is to test the efficacy of a patient-centered, tailored message intervention delivered via virtual technology for increasing colorectal cancer (crc) screening within guidelines among racial/ethnic minority and rural patients. this protocol focuses on the clinical portion of grant nci 1rca207689-01a1

patients will be recruited via a secure, clinical data warehouse to complete a patient-randomized test of the efficacy of the intervention for promoting initial and repeat fit testing. patients identified as eligible will be contacted through mychart to test a web-based, culturally-sensitive virtual human intervention for crc screening. the web-application will provide information to encourage crc screening. therefore, this study is a minimal risk study.

Eligibility criteria:
inclusion criteria: * able to read english or spanish at least at eighth-grade level * have an email account or the ability to receive texts * willingness to be re-contacted * consent to mrr related to crc screening * not remember completing any crc screening within recommended guidelines (i.e., \<10 years for colonoscopy, \<1 year for stool test). * complete a fit test: * a) with a negative result only * b) complete a fit test with a positive result and undergo a completion screening colonoscopy, * or c) complete a colonoscopy only. exclusion criteria: * unable to read english at least at eighth-grade level * doesn't have an email account or the ability to receive texts * unwilling to be re-contacted * unable to consent to mrr related to crc screening * have not had \<10 years for colonoscopy, or 1 year for stool test